Drugs that contain Darolutamide
1. List of Nubeqa drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8975254 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US9657003 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US11046713 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US10711013 | BAYER HEALTHCARE | Androgen receptor modulating compounds |
Oct, 2030
(7 years from now) | |
| US10383853 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| US10010530 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| US11168058 | BAYER HEALTHCARE | Manufacture of a crystalline pharmaceutical product |
Feb, 2038
(15 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10835515 | BAYER HEALTHCARE | Carboxamide derivative and its diastereomers in stable crystalline form |
Jan, 2036
(13 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 30, 2024 |
| New Indication (I) | Aug 5, 2025 |
NCE-1 date: July, 2023
Market Authorisation Date: 30 July, 2019
Treatment: Treatment of patients with non-metastatic castration resistant prostate cancer
Dosage: TABLET;ORAL
More Information on Dosage
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic